| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Laboratory of Cell Biology, National Cancer Institute, NIH, Bethesda, Maryland and 2 Department of Biochemistry, Weill Medical College of Cornell University, New York, New York
Requests for reprints: Michael M. Gottesman, Laboratory of Cell Biology, National Cancer Institute, NIH, Room 2108, Building 37, 37 Convent Drive, Bethesda, MD. Phone: 301-496-1530; Fax: 301-402-0450; E-mail: mgottesman{at}nih.gov.
The clinical utility of cisplatin to treat human malignancies is often limited by the development of drug resistance. We have previously shown that cisplatin-resistant human KB adenocarcinoma cells that are cross-resistant to methotrexate and heavy metals have altered endocytic recycling. In this work, we tracked lipids in the endocytic recycling compartment (ERC) and found that the distribution of the ERC is altered in KB-CP.5 cells compared with parental KB-3-1 cells. A tightly clustered ERC is located near the nucleus in parental KB-3-1 cells but it appears loosely arranged and widely dispersed throughout the cytoplasm in KB-CP.5 cells. The altered distribution of the ERC in KB-CP.5 cells is related to the amount and distribution of stable detyrosinated microtubules (Glu-
-tubulin), as previously shown in Chinese hamster ovary B104-5 cells that carry a temperature-sensitive Glu--tubulin allele. In addition, B104-5 cells with a dispersed ERC under nonpermissive conditions were more resistant to cisplatin compared with B104-5 cells with a clustered ERC under permissive conditions. We conclude that resistance to cisplatin might be due, in part, to reduced uptake of cisplatin resulting from an endocytic defect reflecting defective formation of the ERC, possibly related to a shift in the relative amounts and distributions of stable microtubules. (Cancer Res 2006; 66(4): 2346-53)
This article has been cited by other articles:
|
|
 |
|
  T. Xie, T. Nguyen, M. Hupe, and M. L. Wei Multidrug Resistance Decreases with Mutations of Melanosomal Regulatory Genes Cancer Res., February 1, 2009; 69(3): 992 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-J. Liang, T. Finkel, D.-W. Shen, J.-J. Yin, A. Aszalos, and M. M. Gottesman SIRT1 Contributes in Part to Cisplatin Resistance in Cancer Cells by Altering Mitochondrial Metabolism Mol. Cancer Res., September 1, 2008; 6(9): 1499 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Hillenmeyer, E. Fung, J. Wildenhain, S. E. Pierce, S. Hoon, W. Lee, M. Proctor, R. P. St.Onge, M. Tyers, D. Koller, et al. The Chemical Genomic Portrait of Yeast: Uncovering a Phenotype for All Genes Science, April 18, 2008; 320(5874): 362 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Adachi, T. Nagao, H. I. Ingolfsson, F. R. Maxfield, O. S. Andersen, L. Kopelovich, and I. B. Weinstein The Inhibitory Effect of (-)-Epigallocatechin Gallate on Activation of the Epidermal Growth Factor Receptor Is Associated with Altered Lipid Order in HT29 Colon Cancer Cells Cancer Res., July 1, 2007; 67(13): 6493 - 6501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hara, K. Honda, M. Shitashige, M. Ono, H. Matsuyama, K. Naito, S. Hirohashi, and T. Yamada Mass Spectrometry Analysis of the Native Protein Complex Containing Actinin-4 in Prostate Cancer Cells Mol. Cell. Proteomics, March 1, 2007; 6(3): 479 - 491. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
